{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:27:58Z","timestamp":1772242078019,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["2019-N-1113"],"award-info":[{"award-number":["2019-N-1113"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7192220"],"award-info":[{"award-number":["7192220"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232207"],"award-info":[{"award-number":["7232207"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803051"],"award-info":[{"award-number":["81803051"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073335"],"award-info":[{"award-number":["82073335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173174"],"award-info":[{"award-number":["82173174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.intimp.2023.110288","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:20:10Z","timestamp":1684160410000},"page":"110288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Harnessing NK cell-based immunotherapy to prevent the high-dose radiotherapy-inducing tumor survival recurrence"],"prefix":"10.1016","volume":"120","author":[{"given":"Yan","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1805-140X","authenticated-orcid":false,"given":"Chunxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2023.110288_b0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","article-title":"Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders","volume":"21","author":"Maskalenko","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.intimp.2023.110288_b0010","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2023.110288_b0015","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110288_b0020","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","article-title":"SnapShot: Natural Killer Cells","volume":"180","author":"Crinier","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.110288_b0025","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.mam.2020.100870","article-title":"NK cells and ILCs in tumor immunotherapy","volume":"80","author":"Sivori","year":"2021","journal-title":"Mol. Aspects Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.110288_b0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2010.08.031","article-title":"Natural killer cell education and tolerance","volume":"142","author":"Orr","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.110288_b0035","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110288_b0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol."},{"key":"10.1016\/j.intimp.2023.110288_b0045","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2023.110288_b0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK Cell-Based Immune Checkpoint Inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2023.110288_b0055","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3389\/fimmu.2019.01999","article-title":"NK Cell Dysfunction and Checkpoint Immunotherapy","volume":"10","author":"Bi","year":"2019","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110288_b0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","article-title":"Natural killer cell biology: an update and future directions","volume":"132","author":"Campbell","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2023.110288_b0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","article-title":"CD107a as a functional marker for the identification of natural killer cell activity","volume":"294","author":"Alter","year":"2004","journal-title":"J. Immunol. Methods."},{"key":"10.1016\/j.intimp.2023.110288_b0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-4939-8885-3_7","article-title":"CD107a degranulation assay to evaluate immune cell antitumor activity","volume":"1884","author":"Lorenzo-Herrero","year":"2019","journal-title":"Methods Mol Biol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110288_b0075","first-page":"65","article-title":"Radiotherapy combination opportunities leveraging immunity for the next oncology practice","volume":"67","author":"Herrera","year":"2017","journal-title":"CA: A Cancer J. Clinicians."},{"issue":"6","key":"10.1016\/j.intimp.2023.110288_b0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110288_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000537","article-title":"Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma","volume":"8","author":"Barsoumian","year":"2020","journal-title":"J. Immunotherapy Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2023.110288_b0090","doi-asserted-by":"crossref","first-page":"eabh4050","DOI":"10.1126\/sciadv.abh4050","article-title":"Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8","volume":"8","author":"Walle","year":"2022","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.intimp.2023.110288_b0095","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol."},{"key":"10.1016\/j.intimp.2023.110288_b0100","doi-asserted-by":"crossref","first-page":"14275","DOI":"10.1038\/ncomms14275","article-title":"Dendritic cell MST1 inhibits Th17 differentiation","volume":"8","author":"Li","year":"2017","journal-title":"Nat Commun."},{"issue":"3","key":"10.1016\/j.intimp.2023.110288_b0105","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2023.110288_b0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/cvr\/cvs108","article-title":"CD31: beyond a marker for endothelial cells","volume":"94","author":"Liu","year":"2012","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.intimp.2023.110288_b0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omto.2021.11.016","article-title":"Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges","volume":"24","author":"Poggi","year":"2022","journal-title":"Mol. Ther. Oncolytics."},{"issue":"10","key":"10.1016\/j.intimp.2023.110288_b0120","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","article-title":"Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery","volume":"22","author":"Chang","year":"2021","journal-title":"Lancet Oncol."},{"issue":"Suppl 6","key":"10.1016\/j.intimp.2023.110288_b0125","doi-asserted-by":"crossref","first-page":"s61","DOI":"10.7861\/clinmedicine.14-6-s61","article-title":"Protons and more: state of the art in radiotherapy","volume":"14","author":"Hoskin","year":"2014","journal-title":"Clin. Med. (Lond.)"},{"issue":"1051","key":"10.1016\/j.intimp.2023.110288_b0130","doi-asserted-by":"crossref","first-page":"20150036","DOI":"10.1259\/bjr.20150036","article-title":"LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective","volume":"88","author":"Adebahr","year":"2015","journal-title":"Br. J. Radiol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:05:09Z","timestamp":1761588309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923006112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"alternative-id":["S1567576923006112"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110288","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing NK cell-based immunotherapy to prevent the high-dose radiotherapy-inducing tumor survival recurrence","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110288"}}